NCT04457284View on ClinicalTrials.gov

Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 18, 2020

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Colorectal Adenocarcinoma
Interventions
DRUG

Temozolomide (TMZ)

"TMZ 150 mg/m2 Day 1 - 5 Q4W PO Cycle 1~TMZ 200 mg/m2 Day 1 - 5 Q4W PO Cycle 2 +"

DRUG

Cisplatin

Cisplatin 40 mg/m2 Q2W IV infusion Cycle 1 +

DRUG

Nivolumab

Nivolumab 480 mg Q4W IV infusion Cycle 1 +

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Rockville Centre

11725

Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack

07920

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT04457284 - Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer | Biotech Hunter | Biotech Hunter